adavosertib + omeprazole

Adavosertib + omeprazole is a drug combination primarily utilized in clinical pharmacology studies to evaluate the impact of gastric acid suppression on the pharmacokinetics of adavosertib. Adavosertib (formerly AZD1775 or MK-1775) is a first-in-class, small-molecule inhibitor of the WEE1 kinase, which regulates the G2/M checkpoint in the cell cycle. Because adavosertib exhibits pH-dependent solubility, co-administration with the proton pump inhibitor omeprazole is studied to determine if elevated gastric pH significantly alters the drug's absorption and systemic exposure. These studies are critical for defining dosing recommendations in cancer patients who may require acid-reducing agents.

Other names

AZD1775 + omeprazoleMK-1775 + omeprazole